CMG PharmaceuticalCMG제약
058820 · KOSDAQ · ₩058820 · CMG제약
₩4,520▼ ₩460 (9.24%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩105B | ₩99B | ₩94B | ₩82B | ₩69B |
| Cost of sales | ₩44B | ₩53B | ₩50B | ₩41B | ₩36B |
| Gross profit | ₩61B | ₩46B | ₩44B | ₩41B | ₩33B |
| Operating income | −₩3.7B | ₩1B | ₩3B | ₩3B | ₩1.7B |
| Net income | −₩10B | ₩2.7B | ₩6.5B | −₩388M | ₩3.2B |
| Net income to shareholders | −₩10B | ₩2.7B | ₩6.5B | −₩388M | ₩3.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩306B | ₩303B | ₩242B | ₩213B | ₩199B |
| Current assets | ₩95B | ₩135B | ₩116B | ₩135B | ₩125B |
| Cash and equivalents | ₩6.1B | ₩2.6B | ₩1.2B | ₩4.5B | ₩4.8B |
| Total liabilities | ₩104B | ₩114B | ₩52B | ₩28B | ₩14B |
| Current liabilities | ₩104B | ₩75B | ₩25B | ₩22B | ₩14B |
| Borrowings | ₩72B | ₩80B | ₩26B | ₩6B | ₩153M |
| Total equity | ₩202B | ₩190B | ₩190B | ₩185B | ₩185B |
| Shareholders' equity | ₩202B | ₩190B | ₩190B | ₩185B | ₩185B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩11B | ₩290M | ₩3.9B | ₩5.1B | ₩5.6B |
| Capital spending | ₩30B | ₩28B | ₩12B | ₩8.4B | ₩2.3B |
| Free cash flow | −₩41B | −₩28B | −₩8.5B | −₩3.2B | ₩3.4B |
| Dividends paid | ₩0 | ₩0 | ₩0 | — | — |
Consolidated where available. Amounts in won.
Also known as: CMG Pharmaceutical / CMG제약 / 058820 / KRX:058820
Source: KRX statistical information